3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.
about
Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studiesFLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective studyCurrent frontiers in clinical research application of MALDI imaging mass spectrometry.Utility of [18 F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts.3'-Deoxy-3'-[18F]-Fluorothymidine PET imaging reflects PI3K-mTOR-mediated pro-survival response to targeted therapy in colorectal cancer.Multimodal Imaging of Orthotopic Mouse Model of Endometrial Carcinoma.High-yielding, automated production of 3'-deoxy-3'-[(18)F]fluorothymidine using a modified Bioscan Coincidence FDG reaction module.18F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing Sarcoma.Molecular imaging for early prediction of response to Sorafenib treatment in sarcoma.18F-FLT and 18F-FDG PET-CT imaging in the evaluation of early therapeutic effects of chemotherapy on Walker 256 tumor-bearing rats.A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells.Evaluation of [18F]Fluorothymidine as a Biomarker for Early Therapy Response in a Mouse Model of Colorectal Cancer.Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAFV600E In Vivo.Imaging of molecular target modulation in oncology: challenges of early clinical trials
P2860
Q26778463-63E5DB0C-5E97-4846-A075-9A3B97D0C312Q33889809-0FFE27D7-1C11-47B5-8CC4-61C5B0921DBBQ34777079-DCEEB3ED-2E4A-4509-B26A-CC78C2384EDBQ35031049-B9D3DF38-D5FD-43AE-992D-3DBE930F6D28Q35271098-E7EB66CE-1E0D-4D64-8E35-2CD6896F7778Q35740059-39D6347B-5077-4946-BDD5-EEC6F12DEDEBQ36902928-5D07A10F-C353-4C76-9177-7851911B45BDQ37285365-617732A5-3D80-4EF0-BFB5-D50F3E22CFA6Q37402623-0BE3D866-2ED9-447F-A575-DC3B42CEB313Q37581739-8CDDD288-5F9E-4295-BAEC-E7E704E8EC58Q37707164-7B671E97-B8CE-47E6-8457-4613ECFE9814Q39669240-9F0FC516-6A76-4C66-85DF-B8E140623A30Q51129176-4568302A-E24B-4488-BD47-AC785D8087BCQ57758791-0470A073-4813-41E1-B13B-B11AE2407486
P2860
3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
3'-Deoxy-3'-18F-fluorothymidin ...... l models of colorectal cancer.
@ast
3'-Deoxy-3'-18F-fluorothymidin ...... l models of colorectal cancer.
@en
3'-Deoxy-3'-18F-fluorothymidine PET predicts response to
@nl
type
label
3'-Deoxy-3'-18F-fluorothymidin ...... l models of colorectal cancer.
@ast
3'-Deoxy-3'-18F-fluorothymidin ...... l models of colorectal cancer.
@en
3'-Deoxy-3'-18F-fluorothymidine PET predicts response to
@nl
prefLabel
3'-Deoxy-3'-18F-fluorothymidin ...... l models of colorectal cancer.
@ast
3'-Deoxy-3'-18F-fluorothymidin ...... l models of colorectal cancer.
@en
3'-Deoxy-3'-18F-fluorothymidine PET predicts response to
@nl
P2093
P2860
P1476
3'-Deoxy-3'-18F-fluorothymidin ...... l models of colorectal cancer.
@en
P2093
Eliot T McKinley
H Charles Manning
M Kay Washington
R Adam Smith
Robert J Coffey
Samir A Saleh
P2860
P304
P356
10.2967/JNUMED.112.108456
P407
P577
2013-01-22T00:00:00Z